宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 <sup>*</sup>

doi:10.13523/j.cb.20191013

中国生物工程杂志

2019, Vol. 39

Issue (10): 105-110 DOI: 10.13523/j.cb.20191013

综述

宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 ^*

刘国芳,刘晓志,高健,王志明(

)

华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室石家庄 050015

Effects of Host Cell Residual Proteins on the Quality and Their Quality Control of Monoclonal Antibody

LIU Guo-fang,LIU Xiao-zhi,GAO Jian,WANG Zhi-ming(

)

State Key Laboratory of Antibody Research & Development,New Drug Research and Development Company Ltd,North China Pharmaceutical Corporation,Shijiazhuang 050015,China

全文: PDF(430 KB) HTML

摘要：

以单克隆抗体药物(monoclonal antibodies,mAbs)为代表的生物制品药物销售在不断扩大,并呈现持续上升势头,mAbs的使用为疾病治疗提供了新策略。随着mAbs使用量增大,对产品质量提出了更高要求,随着宿主细胞表达mAbs水平的不断提高,宿主细胞蛋白(host cell proteins,HCP)含量也随之增加,上下游生产工艺面临不断挑战。 HCP所含蛋白质异常复杂,虽然一些HCP可能会被降解,但残留HCP仍会引起药物临床使用中的不良反应,从而影响药物的安全性和有效性。酶联免疫吸附试验(enzyme-linked immunesorbent assays,ELISAs)是目前HCP检测的重要方法之一, ELISAs可以定量检测药物中总HCP含量,但存在局限性。对正在开发的包括LC-MS / MS在内的多种分析方法进行HCP检测,将为药物工艺过程开发和验证提供更多依据。讨论了以CHO(Chinese hamster ovary,中国仓鼠卵巢)细胞系为宿主的mAbs生产中, HCP 的质量控制及检测分析方法的研究进展。

关键词： 单克隆抗体药物; 宿主细胞残留蛋白质; 质量控制; 检测方法

Abstract:

The sales of biologic drugs represented by monoclonal antibodies (mAbs) are expanding and showing a rising trend. The use of mAbs provides a new strategy for disease treatment.With the increase in the use of mAbs,higher requirements are placed on the quality of the product.As the level of mAbs expressed by the host cells continues to increase,the content of host cell proteins (HCP) also increases,and the upstream and downstream production processes are constantly faced challenge.The protein contained in HCP is extremely complicated.Although some HCP may be degraded, residual HCP may cause adverse reactions in the clinical use of the drug, thereby affecting the safety and effectiveness of the drug.Enzyme-linked immune sorbent assays (ELISAs) are important methods for HCP detection. ELISAs can quantitatively measure total HCP levels in drugs, but there are limitations.HCP testing of various analytical methods,including LC-MS/MS,is under development,which will provide more evidence for drug process development and validation.The advances in quality control and assays for HCP production in the production of mAbs hosted by the CHO (Chinese hamster ovary) cell line were discussed.

Key words: Monoclonal antibody drug Host cell protein Quality control Detection method

收稿日期: 2019-01-29 出版日期: 2019-11-12

ZTFLH:

Q819

基金资助: * 国家重大新药创制科技重大专项(2017ZX09306010)

通讯作者: 王志明 E-mail: wzm3994@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘国芳
	刘晓志
	高健
	王志明

引用本文:

刘国芳,刘晓志,高健,王志明. 宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 ^*[J]. 中国生物工程杂志, 2019, 39(10): 105-110.

LIU Guo-fang,LIU Xiao-zhi,GAO Jian,WANG Zhi-ming. Effects of Host Cell Residual Proteins on the Quality and Their Quality Control of Monoclonal Antibody. China Biotechnology, 2019, 39(10): 105-110.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20191013 或 https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I10/105

表1 mAbs产品中常见的宿主残留蛋白质

表2 参与蛋白质聚集的HCP

表3 生产工艺各环节中通常采用降低HCP的策略

表4 HCP的鉴定与检测方法的比较

[1]	Hanania N A, Noonan M, Corren J , et al. Lebrikizumab in moderate-to-severe asthma:pooled data from two randomised placebo-controlled studies. Thorax, 2015,70(8):748-756.
[2]	Wullner D, Zhou L, Bramhall E , et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clinical Immunology, 2010,137(1):5-14.
[3]	Joubert M K, Deshpande M, Yang J , et al. Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics. PLoS One, 2016,11(8):e0159328.
[4]	Bailey-Kellogg C, Gutierrez A H, Moise L , et al. CHOPPI:a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Biotechnology and Bioengineering, 2014,111(11):2170-2182. doi: 10.1002/bit.25286
[5]	Eon-Duval A, Valax P, Solacroup T , et al. Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein:towards a global multi-step design space. Journal of Pharmaceutical Sciences, 2012,101(10):3604-3618. doi: 10.1002/jps.23273
[6]	Bracewell D G, Francis R, Smales C M . The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control. Biotechnology and Bioengineering, 2015,112(9):1727-1737.
[7]	Zhang Y B, Howitt J, Mccorkle S , et al. Protein aggregation during overexpression limited by peptide extensions with large net negative charge. Protein Expression and Purification, 2004,36(2):207-216. doi: 10.1016/j.pep.2004.04.020
[8]	Kim J Y, Kim Y G, Baik J Y , et al. A proteomic approach for identifying cellular proteins interacting with erythropoietin in recombinant Chinese hamster ovary cells. Biotechnology Progress, 2010,26(1):246-251.
[9]	Bee J S, Tie L, Johnson D , et al. Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product. Biotechnology Progress, 2015,31(5):1360-1369.
[10]	Lauer T M, Agrawal N J, Chennamsetty N , et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. Journal of Pharmaceutical Sciences, 2012,101(1):102-115. doi: 10.1002/jps.22758
[11]	Chiu J, Valente K N, Levy N E , et al. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations. Biotechnology and Bioengineering, 2017,114(5):1006-1015.
[12]	Valente K N, Lenhoff A M, Lee K H . Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing. Biotechnology and Bioengineering, 2015,112(6):1232-1242.
[13]	Hogwood C E, Tait A S, Koloteva-Levine N , et al. The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process. Biotechnology and Bioengineering, 2013,110(1):240-251. doi: 10.1002/bit.24607
[14]	Tait A S ,Hogwood C E M,Smales C M,et al. Host cell protein dynamics in the supernatant of a mAb producing CHO cell line. Biotechnology and Bioengineering, 2012,109(4):971-982. doi: 10.1002/bit.24383
[15]	Goey C H ,Tsang J M H,Bell D, et al. Cascading effect in bioprocessing-the impact of mild hypothermia on CHO cell behavior and host cell protein composition. Biotechnology and Bioengineering, 2017,114(12):2771-2781.
[16]	Goey C H, Bell D, Kontoravdi C . Mild hypothermic culture conditions affect residual host cell protein composition post-protein A chromatography. mAbs, 2018,10(3):476-487.
[17]	Pezzini J, Joucla G, Gantier R , et al. Antibody capture by mixed-mode chromatography:a comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins. Journal of Chromatography A, 2011,1218(45):8197-8208. doi: 10.1016/j.chroma.2011.09.036
[18]	Nogal B, Chhiba K, Emery J C . Select host cell proteins coelute with monoclonal antibodies in protein A chromatography. Biotechnology Progress, 2012,28(2):454-458. doi: 10.1002/btpr.1514
[19]	Tarrant R D ,Velez-Suberbie M L,Tait A S, et al.Host cell protein adsorption characteristics during protein A chromatography. Biotechnology Progress, 2012,28(4):1037-1044. doi: 10.1002/btpr.1581
[20]	Zhang Q, Goetze A M, Cui H , et al. Characterization of the co-elution of host cell proteins with monoclonal antibodies during protein A purification. Biotechnology Progress, 2016,32(3):708-717.
[21]	Bee J S, Machiesky L M, Peng L , et al. Identification of an IgG CDR sequence contributing to co-purification of the host cell protease cathepsin D. Biotechnology Progress, 2017,33(1):140-145.
[22]	Gagnon P, Nian R, Lee J , et al. Nonspecific interactions of chromatin with immunoglobulin G and protein A, and their impact on purification performance. Journal of Chromatography A, 2014,1340(2):68-78.
[23]	Gagnon P, Nian R, Yang Y , et al. Non-immunospecific association of immunoglobulin G with chromatin during elution from protein A inflates host contamination, aggregate content,and antibody loss. Journal of Chromatography A, 2015,1408(21):51-60.
[24]	Nian R, Gagnon P . Advance chromatin extraction enhances performance and productivity of cation exchange chromatography-based capture of Immunoglobulin G monoclonal antibodies. Journal of Chromatography A, 2016,1453:54-61.
[25]	Nian R, Zhang W, Tan L , et al. Advance chromatin extraction improves capture performance of protein A affinity chromatography. Journal of Chromatography A, 2016,1431(29):1-7.
[26]	Jin M, Szapiel N, Zhang J , et al. Profiling of host cell proteins by two-dimensional difference gel electrophoresis (2D-DIGE): Implications for downstream process development. Biotechnology and Bioengineering, 2010,105(2):306-316.
[27]	Farrell A, Mittermayr S, Morrissey B , et al. Quantitative host cell protein analysis using two dimensional data independent LC-MS(E). Analytical Chemistry, 2015,87(18):9186-9193.
[28]	Kreimer S, Gao Y, Ray S , et al. Host cell protein profiling by targeted and untargeted analysis of data independent acquisition mass spectrometry data with parallel reaction monitoring verification. Analytical Chemistry, 2017,89(10):5294-5302.
[29]	Chiverton L M, Evans C, Pandhal J , et al. Quantitative definition and monitoring of the host cell protein proteome using iTRAQ - a study of an industrial mAb producing CHO-S cell line. Biotechnology Journal, 2016,11(8):1014-1024.

[1]	李帅鹏,任和,安展飞,杨艳坤,白仲虎. 血栓调节蛋白化学发光免疫分析检测方法的建立^*[J]. 中国生物工程杂志, 2021, 41(4): 30-36.
[2]	吝建华,韩君,徐寒梅. PD-1/PD-L1免疫检查点抗体药物制剂稳定性开发[J]. 中国生物工程杂志, 2020, 40(10): 35-42.
[3]	孟迎迎, 姚长洪, 刘娇, 申培丽, 薛松, 杨青. 微藻生物质成分检测方法评述[J]. 中国生物工程杂志, 2017, 37(7): 133-143.
[4]	任华景, 刘晓志, 王志明, 高健. 中枢神经系统疾病治疗性抗体药物应用进展[J]. 中国生物工程杂志, 2016, 36(9): 54-58.
[5]	王佃亮. 细胞药物的标准及质量控制——细胞药物连载之四[J]. 中国生物工程杂志, 2016, 36(10): 115-121.
[6]	李星, 姚文兵, 徐晨. 聚乙二醇化重组蛋白药物的质量控制[J]. 中国生物工程杂志, 2015, 35(12): 109-114.
[7]	王兰, 夏懋, 高凯. 抗体偶联药物的研究进展与质量控制[J]. 中国生物工程杂志, 2014, 34(4): 85-94.
[8]	傅璐1,黄辉2,陈舒扬1,初波1,刘兢1. 抗ErbB2嵌合抗体chA21大规模纯化工艺的建立及质量研究[J]. 中国生物工程杂志, 2009, 29(07): 68-73.
[9]	刘乐庭, 刘爽, 封燕芸, 陈建国, 于常海. NASBA——一种新型禽流感病毒检测方法[J]. 中国生物工程杂志, 2005, 25(11): 96-99.
[10]	薛迎春. 以Willow Bark为例探讨植物提取物的开发[J]. 中国生物工程杂志, 2004, 24(3): 98-99.
[11]	程从升, 李作生, 余兴龙, 李素, 扈荣良, 江禹, 李尚波, 涂长春. 猪瘟DNA疫苗制备工艺研究[J]. 中国生物工程杂志, 2004, 24(10): 63-69.
[12]	张翊, 王军志, 饶春明. 人降钙素基因相关肽脂质体质量标准的研究[J]. 中国生物工程杂志, 2001, 21(1): 75-78.
[13]	张新咏, 卢圣栋, 林缨. 基因工程药物的质量控制[J]. 中国生物工程杂志, 1997, 17(1): 13-17.
[14]	蔡耘. 基质辅助激光解吸附飞行时间质谱(MALDI-TOF-MS)在生物工程产品质量控制中的应用[J]. 中国生物工程杂志, 1996, 16(4): 23-25.
[15]	汪恩浩. 面向二十一世纪的深圳现代生物技术产业[J]. 中国生物工程杂志, 1994, 14(5): 28-28.

Viewed

Full text

Abstract

Cited

Shared

Discussed